Effects of insulin therapy on weight gain and fat distribution in the HF/HS-STZ rat model of type 2 diabetes

International Journal of Obesity

Volumn 39, Issue 10, 2015, Pages 1531-1538

  Skovso S ^a   Damgaard, J ^b   Fels, J J ^b   Olsen, G S ^b   Wolf, X A ^b   Rolin, B ^b   Holst, J J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; ISOPHANE INSULIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN;

ABDOMINAL FAT; ABDOMINAL WALL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIABETIC OBESITY; DRUG EFFECT; FAT MASS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN TREATMENT; INTRAABDOMINAL FAT; LEAN BODY WEIGHT; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NON ISOPHANE INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SUBCUTANEOUS FAT; SUGAR INTAKE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; BLOOD; BODY COMPOSITION; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; METABOLISM; OBESITY; PATHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD GLUCOSE; BODY COMPOSITION; BODY FAT DISTRIBUTION; CHOLESTEROL; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INTRA-ABDOMINAL FAT; LIPOPROTEINS, HDL; MAGNETIC RESONANCE IMAGING; MALE; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; TOMOGRAPHY, X-RAY COMPUTED; TRIGLYCERIDES; WEIGHT GAIN;

EID: 84943449375     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2015.92     Document Type: Article

References (47)

1. IDF. International Diabetes Federation, IDF Diabetes Atlas, 6th edn, 2013. International Diabetes Federation: Brussels, Belgium, 2014. Available from: http://www. idf.org/diabetesatlas (accessed April 19 2014
2. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J ClinInvest. 2006; 116: 1802-1812.
3. Lindegaard B, Ditlevsen S, Plomgaard P, Mittendorfer B, Pedersen BK. Acute reduction of lipolysis reduces adiponectin and IL-18: evidence from an intervention study with acipimox and insulin. Diabetologia. 2013; 56: 2034-2043.
4. Mehran AE, Templeman NM, Brigidi GS, Lim GE, Chu KY, Hu X, et al. Hyperinsulinemia drives diet-induced obesity independently of brain insulin production. Cell Metab. 2012; 16: 723-737.
5. Timmerman KL, Lee JL, Fujita S, Dhanani S, Dreyer HC, Fry CS, et al. Pharmacological vasodilation improves insulin-stimulated muscle protein anabolism but not glucose utilization in older adults. Diabetes. 2010; 59: 2764-2771.
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352: 837-853.
7. Best JD, Drury PL, Davis TM, Taskinen MR, Kesaniemi YA, Scott R, et al. Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort. Diabetes Care. 2012; 35: 1165-1170.
8. Fonseca V, McDuffie R, Calles J, Cohen RM, Feeney P, Feinglos M, et al. Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. Diabetes Care. 2013; 36: 2162-2168.
9. Pontiroli AE, Miele L, Morabito A. Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-Analysis. Diabetes Obes Metab. 2011; 13: 1008-1019.
10. Shah PK, Mudaliar S, Chang AR, Aroda V, Andre M, Burke P, et al. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes. Diabetes Obes Metab. 2011; 13: 505-510.
11. Yki-Jarvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J, Marjanen T, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997; 82: 4037-4043.
12. Field AE, Coakley EH, Must A, Spadano JL, Laird N, Dietz WH, et al. Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Inter Med. 2001; 161: 1581-1586.
13. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983; 67: 968-977.
14. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006; 444: 875-880.
15. Yusuf S, Hawken S, Ounpuu S, Bautista L, Franzosi MG, Commerford P, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005; 366: 1640-1649.
16. Davies MJ, Derezinski T, Pedersen CB, Clauson P. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. Diabetes Technol Ther. 2008; 10: 273-277.
17. Fajardo Montanana C, Hernandez Herrero C, Rivas Fernandez M. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabetic Med. 2008; 25: 916-923.
18. Rosenstock J, Lorber DL, Gnudi L, Howard CP, Bilheimer DW, Chang PC, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010; 375: 2244-2253.
19. Skovsø S. Modeling type 2 diabetes in rats using high fat diet and streptozotocin. J Diabetes Invest. 2014; 5: 349-358.
20. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. 1956. Nutrition. 1999; 15: 89-90.
21. Vague J. Sexual differentiation A determinant factor of the forms of obesity. 1947. Obesity Res. 1996; 4: 201-203.
22. Demerath EW, Reed D, Rogers N, Sun SS, Lee M, Choh AC, et al. Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels. Am J Clin Nutr. 2008; 88: 1263-1271.
23. Klein S, Fontana L, Young VL, Coggan AR, Kilo C, Patterson BW, et al. Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N Engl J Med. 2004; 350: 2549-2557.
24. Marques MD, Santos RD, Parga JR, Rocha-Filho JA, Quaglia LA, Miname MH, et al. Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography. Atherosclerosis. 2010; 209: 481-486.
25. Newton Jr RL, Bouchard C, Bray G, Greenway F, Johnson WD, Ravussin E, et al. Abdominal adiposity depots are correlates of adverse cardiometabolic risk factors in Caucasian and African-American adults. Nutr Diabetes. 2011; 1: e2.
26. Manolopoulos KN, Karpe F, Frayn KN. Gluteofemoral body fat as a determinant of metabolic health. Int J Obes (Lond) 2010; 34: 949-959.
27. Guillen J. FELASA guidelines and recommendations. J Am Assoc Lab Anim Sci. 2012; 51: 311-321.
28. van Gammeren AJ, van Gool N, de Groot MJ, Cobbaert CM. Analytical performance evaluation of the Cobas 6000 analyzer-special emphasis on trueness verification. Clin Chem Lab Med. 2008; 46: 863-871.
29. Conde-Sanchez M, Roldan-Fontana E, Chueca-Porcuna N, Pardo S, Porras-Gracia J. Analytical performance evaluation of a particle-enhanced turbidimetric cystatin C assay on the Roche COBAS 6000 analyzer. Clin Biochem. 2010; 43: 921-925.
30. Association AD. Standards of medical care in diabetes-2014. Diabetes Care. 2014; 37 (Suppl 1): S14-S80.
31. Juurinen L, Tiikkainen M, Hakkinen AM, Hakkarainen A, Yki-Jarvinen H. Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes. Am J Physiol Endocrinol Metab. 2007; 292: E829-E835.
32. Son JW, Jeong HK, Lee SS, Kim SR, Cha BY, Son HY, et al. The effect of early intensive insulin therapy on body fat distribution and beta-cell function in newly diagnosed type 2 diabetes. Endocr Res. 2013; 38: 160-167.
33. Takei I, Takayama S, Yamauchi A, Nakamoto S, Kitamura Y, Katsukawa F, et al. Effect of insulin therapy on body fat distribution in NIDDM patients with secondary sulfonylurea failure: a preliminary report. Eur J Clin Nutr. 1998; 52: 153-154.
34. Elsayed A, ElBebely S, Galal A. Insulin therapy induced adposity evaluated by computed tomography is not visceral. Pak J Med Sci. 2007; 23: 161-166.
35. Tang A, Rabasa-Lhoret R, Castel H, Wartelle-Bladou C, Gilbert G, Massicotte-Tisluck K, et al. Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat As Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial. Diabetes Care. 2015; e-pub ahead of print 26 March 2015.
36. Bolinder J, Kager L, Ostman J, Arner P. Differences at the receptor and postreceptor levels between human omental and subcutaneous adipose tissue in the action of insulin on lipolysis. Diabetes. 1983; 32: 117-123.
37. Kraunsoe R, Boushel R, Hansen CN, Schjerling P, Qvortrup K, Stockel M, et al. Mitochondrial respiration in subcutaneous and visceral adipose tissue from patients with morbid obesity. J Physiol. 2010; 588 (Pt 12): 2023-2032.
38. Livingston JN, Lerea KM, Bolinder J, Kager L, Backman L, Arner P. Binding and molecular weight properties of the insulin receptor from omental and subcutaneous adipocytes in human obesity. Diabetologia. 1984; 27: 447-453.
39. Marin P, Andersson B, Ottosson M, Olbe L, Chowdhury B, Kvist H, et al. The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism. 1992; 41: 1242-1248.
40. Zierath JR, Livingston JN, Thorne A, Bolinder J, Reynisdottir S, Lonnqvist F, et al. Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway. Diabetologia. 1998; 41: 1343-1354.
41. Kaess BM, Pedley A, Massaro JM, Murabito J, Hoffmann U, Fox CS. The ratio of visceral to subcutaneous fat, a metric of body fat distribution, is a unique correlate of cardiometabolic risk. Diabetologia. 2012; 55: 2622-2630.
42. Galland F, Duvillard L, Petit JM, Lagrost L, Vaillant G, Brun JM, et al. Effect of insulin treatment on plasma oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients. Diabetes Metab. 2006; 32: 625-631.
43. Li F, Zhao T, Wen X. Changes in serum adiponectin concentrations and endothelial function after intensive insulin treatment in people with newly diagnosed type 2 diabetes: a pilot study. Diabetes Res Clin Pract. 2011; 94: 186-192.
44. Hafiane A, Genest J. HDL, atherosclerosis, and emerging therapies. Cholesterol. 2013; 2013: 891403.
45. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013; 61: 427-436.
46. Sparks JD, Shaw WN, Corsetti JP, Bolognino M, Pesek JF, Sparks CE. Insulin-Treated Zucker diabetic fatty rats retain the hypertriglyceridemia associated with obesity. Metabolism. 2000; 49: 1424-1430.
47. Erion DM, Ignatova ID, Yonemitsu S, Nagai Y, Chatterjee P, Weismann D, et al. Prevention of hepatic steatosis and hepatic insulin resistance by knockdown of cAMP response element-binding protein. Cell Metab. 2009; 10: 499-506.